Neoadjuvant radiation therapy for the management of myoepithelial carcinoma of the upper extremity

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Myoepithelial tumors of the soft tissue are a rare tumor displaying myoepithelial elements and lacking obvious ductal differentiation. The rarity of these precludes any evidence-based consensus regarding optimal management. Nevertheless, the current approach to these lesions begins with amputation or complete excision. The efficacy of neoadjuvant or adjuvant radiation therapy or chemotherapy has not been established. Here, we present the first report to the authors’ knowledge of neoadjuvant radiation therapy for the treatment of this rare soft tissue neoplasm and review the management and outcomes of published cases of myoepithelial carcinoma. A patient with a soft tissue myoepithelial carcinoma that declined both amputation and chemotherapy was treated with neoadjuvant radiation therapy and wide surgical excision followed by a brachytherapy boost to the resected tumor bed. Neoadjuvant radiation therapy resulted in an excellent response with extensive treatment-related changes consisting predominantly of fibrosis, hyalinization and hemorrhage and only 10% residual viable myoepithelial carcinoma present in the surgical specimen.

Original languageEnglish (US)
Pages (from-to)854-862
Number of pages9
JournalInternational Journal of Cancer
Volume142
Issue number4
DOIs
StatePublished - Feb 15 2018

Fingerprint

Neoadjuvant Therapy
Upper Extremity
Radiotherapy
Myoepithelioma
Carcinoma
Amputation
Soft Tissue Neoplasms
Drug Therapy
Brachytherapy
Fibrosis
Hemorrhage
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{e7358103395b41abaa30e0dd0b61d5a7,
title = "Neoadjuvant radiation therapy for the management of myoepithelial carcinoma of the upper extremity",
abstract = "Myoepithelial tumors of the soft tissue are a rare tumor displaying myoepithelial elements and lacking obvious ductal differentiation. The rarity of these precludes any evidence-based consensus regarding optimal management. Nevertheless, the current approach to these lesions begins with amputation or complete excision. The efficacy of neoadjuvant or adjuvant radiation therapy or chemotherapy has not been established. Here, we present the first report to the authors’ knowledge of neoadjuvant radiation therapy for the treatment of this rare soft tissue neoplasm and review the management and outcomes of published cases of myoepithelial carcinoma. A patient with a soft tissue myoepithelial carcinoma that declined both amputation and chemotherapy was treated with neoadjuvant radiation therapy and wide surgical excision followed by a brachytherapy boost to the resected tumor bed. Neoadjuvant radiation therapy resulted in an excellent response with extensive treatment-related changes consisting predominantly of fibrosis, hyalinization and hemorrhage and only 10{\%} residual viable myoepithelial carcinoma present in the surgical specimen.",
author = "Rafi Kabarriti and Quinn, {Thomas J.} and Ewart, {Michelle R.} and Mehta, {Keyur J.} and Craig Lomita and Geller, {David S.} and Shalom Kalnicki and Fox, {Jana L.}",
year = "2018",
month = "2",
day = "15",
doi = "10.1002/ijc.31101",
language = "English (US)",
volume = "142",
pages = "854--862",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant radiation therapy for the management of myoepithelial carcinoma of the upper extremity

AU - Kabarriti, Rafi

AU - Quinn, Thomas J.

AU - Ewart, Michelle R.

AU - Mehta, Keyur J.

AU - Lomita, Craig

AU - Geller, David S.

AU - Kalnicki, Shalom

AU - Fox, Jana L.

PY - 2018/2/15

Y1 - 2018/2/15

N2 - Myoepithelial tumors of the soft tissue are a rare tumor displaying myoepithelial elements and lacking obvious ductal differentiation. The rarity of these precludes any evidence-based consensus regarding optimal management. Nevertheless, the current approach to these lesions begins with amputation or complete excision. The efficacy of neoadjuvant or adjuvant radiation therapy or chemotherapy has not been established. Here, we present the first report to the authors’ knowledge of neoadjuvant radiation therapy for the treatment of this rare soft tissue neoplasm and review the management and outcomes of published cases of myoepithelial carcinoma. A patient with a soft tissue myoepithelial carcinoma that declined both amputation and chemotherapy was treated with neoadjuvant radiation therapy and wide surgical excision followed by a brachytherapy boost to the resected tumor bed. Neoadjuvant radiation therapy resulted in an excellent response with extensive treatment-related changes consisting predominantly of fibrosis, hyalinization and hemorrhage and only 10% residual viable myoepithelial carcinoma present in the surgical specimen.

AB - Myoepithelial tumors of the soft tissue are a rare tumor displaying myoepithelial elements and lacking obvious ductal differentiation. The rarity of these precludes any evidence-based consensus regarding optimal management. Nevertheless, the current approach to these lesions begins with amputation or complete excision. The efficacy of neoadjuvant or adjuvant radiation therapy or chemotherapy has not been established. Here, we present the first report to the authors’ knowledge of neoadjuvant radiation therapy for the treatment of this rare soft tissue neoplasm and review the management and outcomes of published cases of myoepithelial carcinoma. A patient with a soft tissue myoepithelial carcinoma that declined both amputation and chemotherapy was treated with neoadjuvant radiation therapy and wide surgical excision followed by a brachytherapy boost to the resected tumor bed. Neoadjuvant radiation therapy resulted in an excellent response with extensive treatment-related changes consisting predominantly of fibrosis, hyalinization and hemorrhage and only 10% residual viable myoepithelial carcinoma present in the surgical specimen.

UR - http://www.scopus.com/inward/record.url?scp=85038850830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038850830&partnerID=8YFLogxK

U2 - 10.1002/ijc.31101

DO - 10.1002/ijc.31101

M3 - Article

C2 - 29023697

AN - SCOPUS:85038850830

VL - 142

SP - 854

EP - 862

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -